Jaguar Health Inc (JAGX)

• $1.27

  $1.34

  $1.29
  

  1.49%

  Downside

  Day's Volatility :5.16%

  Upside

  3.73%

  
• $0.95

  $31.74

  $1.29
  

  26.35%

  Downside

  52 Weeks Volatility :97.01%

  Upside

  95.94%

  

Returns

What analysts predicted

Upside of 1024.03%

• Geode Capital Management, LLC

  0.33%

• Perritt Capital Management Inc.

  0.27%

• Squarepoint Ops LLC

  0.24%

• Commonwealth Equity Services Inc

  0.12%

• Vanguard Group Inc

  0.11%

• Tower Research Capital LLC

  0.03%

jaguar health, inc. is a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. our wholly-owned subsidiary, napo pharmaceuticals, inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. our mytesi® (crofelemer) product is approved by the u.s. fda for the symptomatic relief of noninfectious diarrhea in adults with hiv/aids on antiretroviral therapy. canalevia™ is our lead animal prescription drug candidate, intended for treatment of various forms of diarrhea in dogs. equilevia™ is jaguar’s non-prescription product for total gut health in equine athletes. to read our full social media policy, please visit https://jaguar.health/social-media-policy/